Skip to main content

Table 2 Patient characteristics and incidence (episode/1000 admission)

From: A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China

  All patients Child patients(0-16 years) Adult patients(> 16 years) P*
(n = 201)
100.0%
(n = 35)
17.4%
(n = 166)
82.6%
Age (median, range) 65 years
(1 day, 92 years)
1 day
(1 day,5 years)
61 years
(18 years, 92 years)
< 0.001
Gender (male:female) 114:87 22:13 92:74 0.420
Length of hospital stay(days) 36.9 ± 39.5 41.5 ± 20.9 30.6 ± 39.6 0.117
Underlying comorbidities (n, %)
 Gastrointestinal perforation 24 (11.9) 2 (5.7) 22(13.3) 0.211
Respiratory dysfunctiona 58 (28.9) 3 (8.6) 55 (33.1) 0.004
Pulmonary infection 100(49.8) 24 (68.6) 76(45.8) 0.014
Cardiovascular disease 86 (42.8) 3(8.6) 83 (50.0) < 0.001
Neurological diseases 78 (38.8) 24(68.6) 54 (32.5) < 0.001
Gastrointestinal pathologyb 58(28.9) 2(5.7) 43 (25.9) 0.001
 Chronic/acute liver disease 49(24.4) 9(25.7) 40(24.1) 0.839
Chronic/acute renal failurec 91(45.3) 9(25.7) 82 (49.4) 0.011
 Solid tumour 15(7.5) 0(0) 15(9.0) 0.065
 Haematological malignancy 11 (5.5) 2 (5.7) 9(5.4) 0.697
Congenital malformations/syndromes 6(3.0) 3 (8.6) 3 (1.8) < 0.001
Diabetes mellitus 60 (29.9) 0(0) 60 (36.1) < 0.001
Hematologic (nonmalignant) 29 (14.4) 10 (28.6) 19 (11.4) 0.009
 HIV/AIDS 10 (5.0) 0(0) 10 (6.0) 0.136
 Severe trauma 17(8.5) 2 (5.7) 15 (9.0) 0.521
Risk factors (n, %)
Presence of CVCd 77(38.3) 7(20.0) 70(42.2) 0.014
Other invasive catheters 60(29.9) 5(14.3) 55(33.1) 0.027
Mechanical ventilation 87(43.3) 21 (60.0) 66(39.8) 0.028
 Receipt of corticosteroidse 42 (20.9) 9(25.7) 33(19.9) 0.440
 Total parenteral nutrition 95(47.3) 18(51.4) 77(46.4) 0.587
 Malnutrition 55(27.4) 9(25.7) 46(27.7) 0.810
 Chemotherapy 20(10.0) 2 (5.7) 18(10.8) 0.357
Hemodialysis 30(16.9) 0(0) 30(18.1) 0.006
Abdominal surgeryf 31 (15.4) 0 (0) 31 (18.7) 0.005
ICU/PICU/NICU 81(40.3) 35 (100.0) 46 (27.7) < 0.001
 Neutropeniag 16(8.0) 0 (0) 16(9.6) 0.056
Concomitant bacterial infections 110(54.7) 30 (85.7) 80 (48.2) < 0.001
 Septic shock 39 (19.4) 3 (8.6) 36(21.7) 0.075
Broad-spectrum antibiotics 179 (89.1) 35 (100.0) 144 (86.7) 0.022
Treatment with antifungal agents 114 (56.7) 27(77.1) 87(52.4) 0.007
C. albicans 81(40.3) 16(45.7) 65(39.2) 0.472
C. glabrata 73(36.3) 18(51.4) 55(33.1) 0.041
C. tropicalis 28(13.9) 0(0) 28(16.9) 0.009
 Death 41(20.4) 4(11.4) 37(22.3) 0.113
Incidence(n,episodes/1000 admissions)
 2013 14(0.20) 0(0.0) 14(0.24) 0.248
 2014 23(0.22) 1(0.09) 22(0.24) 0.507
 2015 29(0.27) 6(0.53) 23(0.24) 0.117
2016 42(0.37) 12(1.07) 30(0.29) 0.001
2017 38(0.32) 12(1.06) 26(0.24) < 0.001
 2018 20(0.16) 3(0.21) 17(0.15) 0.480
 2019 35(0.26) 1(0.08) 34(0.27) 0.252
Mean annual incidence 201(0.26) 35(0.42) 166(0.24) 0.002
  1. *Statistical results of demographic characteristics of pediatric and adult patients
  2. a Includes the following diseases: chronic obstructive pulmonary disease and acute respiratory distress syndrome
  3. b Includes the following diseases: cholecystitis, pancreatitis, and peritonitis
  4. c Chronic/Acute renal failure is the permanent or sudden and often temporary loss of kidney function with N waste retention and hypourocrinia
  5. d CVC central venous catheter
  6. ea dose equivalent to the prednisone dosage of 0.3 mg/kg/day for at least 14 days
  7. f including: gastrointestinal perforations, severe acute pancreatitis and complex ventral hernia
  8. g Neutropenia is the absolute neutrophil count, that is, < 500 cells/μl